ClinicalTrials.gg
RecruitingNCT07881224Updated Oct 19, 2026

A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects

A Phase 1 interventional study of Fosmanogepix and Placebo in Healthy Adult Participants, sponsored by Basilea Pharmaceutica. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, fixed-sequence, multiple-dose study in approximately 42 healthy adult participants. The study will be conducted in two parts. Part 1 will evaluate the effect of fosmanogepix, through exposure to its active moiety manogepix, on selected CYP enzymes and on the concentration-QT interval corrected for heart rate (QTc). Part 2 will evaluate the effect of manogepix on CYP2C8 and on selected drug transporters. The maximum study duration will be approximately 13.5 weeks for participants in Part 1 and approximately 12 weeks for participants in Part 2.

02

Conditions studied

  • Healthy Adult Participants

Keywords

  • Drug-drug interaction study
  • Pharmacokinetics
  • Healthy adults
  • Fosmanogepix
  • Manogepix
03

In context

Lead sponsor

Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • of 18 to 30 kg/m2, inclusive, and a total body weight > 50 kg at screening
  • Healthy, as determined by medical history, physical examination, and other procedures, including blood pressure and pulse rate, 12-lead , clinical laboratory tests (hematology, clinical chemistry, coagulation, urinalysis), and an estimated (eGFR) ≥ 80 mL/min/1.73m2 (CKD-EPI formula), at Screening and Day -2.
  • Women of must agree to use highly effective forms of during treatment and observation.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
  • Active infection.
  • Any condition possibly affecting drug absorption.
  • History of (HIV) infection, , or ; positive testing for HIV, HBsAg, HBcAb, HCVAb, and syphilis
  • Subjects who are pregnant, breastfeeding, or plan to become pregnant during the study.

Medical history of neurological disorders, including abnormal movements or seizures.

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior, or laboratory abnormality that may increase the risk of study participation or, in the Investigator's judgment, make the subject inappropriate for the study.
  • History of allergy or or other to any of the drugs to be administered, or to one of the components of the study drugs, as determined by the Investigator.
  • History of risk factors for , Torsades de Pointes, or uncorrected hypokalemia/hypomagnesemia.
  • Previous administration of an drug (including a vaccine) within 60 days or five half-lives (whichever is longer) prior to the first study drug administration on Day 1.
  • For Part 1 only, poor metabolizers of CYP2D6 (*4/*4; *4/*5; *5/*5), CYP2C9 (*2/*2; *2/*3; *3/*3), and/or CYP2C19 (*2/*2) (determined at Screening or from available historical data).
  • Supine systolic blood pressure (SBP) > 140 mmHg or diastolic blood pressure (DBP) > 90 mmHg, and pulse rate > 100 beats per minute (bpm) or \< 40 bpm Supine 12-lead demonstrating any of the following clinically-relevant abnormalities that may affect subject safety or interpretation of the study results: QTcF interval > 450 msec, QRS interval > 120 msec, complete left bundle branch block, signs of an acute or indeterminate-age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second- or third-degree AV block, or serious bradyarrhythmias or tachyarrhythmias
  • Subjects with or ALT > 1.0 × .
  • Blood (excluding plasma) donation or blood loss > 500 mL within 60 days prior to Screening.
  • History of alcohol abuse or binge drinking and/or any other illicit drug abuse or dependence.
  • Use of tobacco or nicotine-containing products or devices within 3 months of Screening.
  • Caffeine consumption ≥ 800 mg per day at Screening.
  • Use of prescription/non-prescription (including vaccines) drugs or dietary/herbal supplements within 21 days (or five half-lives, whichever is longer) prior to Day -2, except for hormonal , or paracetamol up to 1,500 mg/day.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Part 1

    Fosmanogepix or placebo + probe substrate cocktail Participants will receive study intervention as follows: * Day 1 and Day 22: probe substrate cocktail * Days 5 to 24: Placebo or fosmanogepix

    Drug: Fosmanogepix · Other: Placebo · Other: The medicine cocktail (caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan and midazolam)

  • Experimental
    Part 2

    Fosmanogepix + Probe substrates Participants will receive study intervention as follows: * Day 1 and Day 19: Repaglinide * Day 2 and Day 20: Rosuvastatin and Digoxin * Days 6 to 21: Fosmanogepix

    Drug: Fosmanogepix · Other: Probe substrates (repaglinide, rosuvastatin, and digoxin)

Interventions

  • Fosmanogepix will be administered as an intravenous infusion or as an oral tablet

  • OtherPlacebo

    Placebo will be administered as an intravenous infusion or as an oral tablet

  • OtherThe medicine cocktail (caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan and midazolam)

    The medicine cocktail will be administered as tablet, capsule, or drink to be swallowed

  • OtherProbe substrates (repaglinide, rosuvastatin, and digoxin)

    Probe substrates will be administered as oral tablets

06

What researchers measure

Primary outcomes

  1. Part 1: Maximum Plasma Concentration (Cmax) of the medicine cocktail when administered alone or in combination with manogepix at steady state

    The effect of fosmanogepix will be checked by comparing the blood levels of the medicine cocktail when taken alone or after administration of fosmanogepix.

    Time frame: At Day 1 and Day 22

  2. Part 1: Area under the concentration-time curve (AUC) of the medicine cocktail when administered alone or in combination with manogepix at steady state

    The effect of fosmanogepix will be checked by comparing the blood levels of the medicine cocktail when taken alone or after administration of fosmanogepix.

    Time frame: At Day 1 and Day 22

  3. Part 2: Maximum Plasma Concentration (Cmax) of probe substrate cocktail when administered alone or in combination with manogepix at steady state

    The effect of fosmanogepix will be checked by comparing the blood levels of probe substrate cocktail when taken alone or after administration of fosmanogepix.

    Time frame: From Day 1 to Day 20

  4. Part 2: Area under the concentration-time curve (AUC) of probe substrate cocktail when administered alone or in combination with manogepix at steady state

    The effect of fosmanogepix will be checked by comparing the blood levels of of probe substrate cocktail when taken alone or after administration of fosmanogepix.

    Time frame: From Day 1 to Day 20

Secondary outcomes

  1. Part 1: Placebo-corrected change from baseline in the heart-rate corrected QT interval using Fridericia's formula

    Electrocardiogram (ECG) monitoring will be performed during placebo and fosmanogepix administration.

    Time frame: From Day 5 to Day 12

  2. Number of participants reporting treatment emergent adverse events (TEAEs)

    To evaluate the safety and tolerability of fosmanogepix when administered in combination with the medicine cocktail or probe substrates cocktail

    Time frame: From screening to week 13.5

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2026
First posted
Oct 19, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Mar 9, 2027
CompletionEst.
Mar 9, 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07881224
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Oct 19, 2026
Start date
Oct 1, 2026
Primary completion
Mar 9, 2027 (estimated)
Completion
Mar 9, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Thomas Kaindl, MD
Contact
thomas.kaindl@basilea.com
+41615671505
Thomas Kaindl, MD
study director · Basilea Pharmaceutica International Ltd, Allschwil

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosmanogepix

Start the discussion